Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Transgenic Obtains Patent For Pancreatic Cancer Antibody Diagnostic Technology

This article was originally published in PharmAsia News

Executive Summary

Japanese biotech venture company Transgenic obtained a patent for pancreatic cancer antibody diagnostic technology. The technology uses antibodies to detect a protein unique to pancreatic cancer patients. Transgenic developed the technology through a joint research project with Japan's National Cancer Center in 2007. Using genetically engineered mice, Transgenic developed the antibody that can be easily combined with the protein. Currently there are few cancer makers for pancreatic cancer diagnose. (Click here for more - Japanese language

You may also be interested in...



Mylan Bids To Win EU Approval For Upjohn Merger

Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.

IGBA Criticizes Export Restrictions

National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.

Italy’s Dompé Taking Legal Action Over COVID-19 Fake News

Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.

UsernamePublicRestriction

Register

SC072044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel